Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The largest whole-genome sequencing study thus far has revealed myriad actionable alterations and potential biomarkers for 33 cancer types, but various logistical, technical and economic challenges must be overcome before this technique can become standard of care.
CAR T cell therapy has transformed the treatment of B cell cancers and is now being pursued by biotech companies for conditions as varied as systemic lupus erythematosus, diabetes and organ rejection.
The first report from the Cancer Programme of the 100,000 Genomes Project presents whole-genome sequencing profiles of 13,880 solid tumors spanning 33 cancer types, combined with real-world clinical data, providing insights for precision oncology.
Two malaria vaccines are approved and several prophylactic antibodies are in development, but a combination of strategies tailored to different epidemiological situations will be needed if malaria is to be eliminated.
Many countries are short of healthcare workers, thousands of whom have quit since the COVID-19 pandemic, but the global migration of doctors and nurses to work in high-income countries is hurting the world’s poorest people.
Social determinants of health can only be tackled through collaborations between public health leaders, economists, sociologists, and other non-medical stakeholders, as well as involvement from the community.
Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.
DigiONE is a pilot European learning health system in precision oncology that aims to identify optimal cancer treatments by learning from every patient, not just those in trials, through privacy-preserving interrogation of their standardized routine electronic health records.
A meta-analysis using the Burden of Proof method reported consistent evidence supporting harmful associations between exposures to secondhand smoke and nine health outcomes.
In a phase 1 trial, a lymph node-targeting mutant KRAS peptide vaccine combined with CpG adjuvant is safe, reduces expression of tumor biomarkers and elicits mutant KRAS-specific T cells in patients with pancreatic cancer and colorectal cancer.
Systematic evaluation of literature in four databases to generate an evidence gap map for noncommunicable disease interventions in children and adolescents shows that over 90% of studies have been done in high-income countries and that evidence for interventions for mental health conditions, obesity and substance misuse is lacking globally.
A six-tiered governance framework for federated health data, with varying levels of data access and sharing, is proposed to facilitate the use of health data held within more than one secure environment, while preserving privacy.
In this prespecified analysis of the ongoing TORCHLIGHT phase 3 trial, first-line treatment with toripalimab and nab-paclitaxel in patients with advanced triple-negative breast cancer led to significantly longer progression-free survival in the PD-L1-positive population compared to nab-paclitaxel alone.
A neoadjuvant treatment regimen of anti-PD-L1 monotherapy followed by anti-PD-L1 plus chemotherapy was well tolerated and led to a major pathologic response rate of 70% in patients with resectable gastric or gastroesophageal junction adenocarcinoma.